Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177554 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00177554 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 60 participants.
The verdict
NCT00177554, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
Interventions
- DRUG Chemotherapy and Radioimmunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177554
The ClinicalTrials.gov registry entry for NCT00177554 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chemotherapy and Radioimmunotherapy is the first listed.
NCT00177554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177554 about?
NCT00177554 is a clinical study titled "Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma". The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
What is the current status of trial NCT00177554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2003-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00177554?
The interventions under investigation include: Chemotherapy and Radioimmunotherapy (DRUG).
Who is sponsoring clinical trial NCT00177554?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.